Selective suppression of host T cell and macrophage activities during 7,12-dimethylbenz[a]anthracene-induced

Gan
|October 1, 1982
PubMed

Insights

7,12-dimethylbenz[a]anthracene (DMBA) suppresses immune responses by primarily targeting antigen-presenting macrophages. This leads to reduced T-cell activation and secondary suppression of B-cell development, impacting antibody production.

Area of Science:

  • Immunology
  • Toxicology
  • Cellular Biology

Background:

  • 7,12-dimethylbenz[a]anthracene (DMBA) is known to induce immunosuppression.
  • The precise cellular mechanisms underlying DMBA-induced immune suppression require elucidation.

Purpose of the Study:

  • To investigate the cellular targets of DMBA-induced immunosuppression.
  • To differentiate the effects of DMBA on T cells, B cells, and macrophages.

Main Methods:

  • In vivo and in vitro assay systems were employed.
  • Adoptive cell transfer and thymus-dependent/independent antibody response assays were utilized.
  • Macrophage antigen-presenting capacity and T-cell proliferation were assessed.

Main Results:

  • DMBA suppressed both hapten-primed B cells and carrier-primed helper T cells in vivo.
  • B cell activity was not suppressed when using thymus-independent antigens.
  • Antigen-primed T cells from DMBA-treated mice showed reduced proliferation.
  • Macrophages from DMBA-treated mice exhibited impaired T-cell activation.

Conclusions:

  • DMBA primarily targets antigen-presenting macrophages, not T cells directly.
  • Suppression of T-cell activity is a consequence of macrophage dysfunction.
  • Impaired B-cell development is a secondary effect of DMBA-induced immunosuppression via macrophage and T-cell pathways.